Search Results - "Ohki, Emiko"

Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings by Ueno, Naomi, Banno, Shigeo, Endo, Yutaka, Tamura, Motoko, Sugaya, Katsuko, Hashigaki, Satoshi, Ohki, Emiko, Yoshimura, Akinobu, Gemma, Akihiko

“…Post-marketing surveillance (PMS) was performed in Japan to obtain information on the safety and efficacy of crizotinib. Target patients included almost all…”
Get full text

Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study by Ito, Tetsuhide, Tori, Masayuki, Hashigaki, Satoshi, Kimura, Nobuyuki, Sato, Kazuo, Ohki, Emiko, Sawaki, Akira, Okusaka, Takuji

“…In an interim analysis of a Phase II trial in Japanese patients with pancreatic neuroendocrine tumors (panNETs), sunitinib demonstrated antitumor activity with…”
Get full text

Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitalium by Terada, Michinori, Ohki, Emiko, Yamagishi, Yuka, Izumi, Koji, Mikamo, Hiroshige

“…Abstract Mycoplasma genitalium has been shown to be one of the pathogens responsible for uterine cervicitis by many studies. However, there are no clinical…”
Get full text

Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor by Komatsu, Yoshito, Ohki, Emiko, Ueno, Naomi, Yoshida, Ai, Toyoshima, Yasuharu, Ueda, Eiji, Houzawa, Hiroyuki, Togo, Kanae, Nishida, Toshirou

“…This study was conducted to expand the sunitinib safety database in Japanese imatinib-resistant/-intolerant gastrointestinal stromal tumor patients…”
Get full text

Safety of crizotinib in 892 Japanese ALK-positive advanced NSCLC patients: Interim report of post-marketing surveillance by Okamoto, Isamu, Nakagawa, Kazuhiko, Ohe, Yuichiro, Ueno, Naomi, Banno, Shigeo, Endo, Yutaka, Ohki, Emiko, Gemma, Akihiko

Get full text

MC-3 Introduce career support, lifework management system and commitment to employees' satisfaction at a foreign pharmaceutical manufacturer by Ohki, Emiko

Get full text

Phase I study of TLR9 agonist PF‐3512676 in combination with carboplatin and paclitaxel in patients with advanced non‐small‐cell lung cancer by Yamada, Kazuhiko, Nakao, Masao, Fukuyama, Chikara, Nokihara, Hiroshi, Yamamoto, Noboru, Sekine, Ikuo, Kunitoh, Hideo, Ohe, Yuichiro, Ohki, Emiko, Hashimoto, Junichi, Tamura, Tomohide

“…This phase I, open‐label study investigated the Toll‐like receptor 9 agonist, PF‐3512676, in combination with carboplatin and paclitaxel in Japanese patients…”
Get full text

Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections by Ohki, Emiko, Yamagishi, Yuka, Mikamo, Hiroshige

“…Abstract The efficacy of fluoroquinolones (FQs) correlates with the pharmacokinetic/pharmacodynamic (PK–PD) parameter, AUC/MIC. To our knowledge, however, no…”
Get full text

Fungal peritonitis associated with Curvularia geniculata and Pithomyces species in a patient with vulvar cancer who was successfully treated with oral voriconazole by Terada, Michinori, Ohki, Emiko, Yamagishi, Yuka, Nishiyama, Yayoi, Satoh, Kazuo, Uchida, Katsuhisa, Yamaguchi, Hideyo, Mikamo, Hiroshige

Get full text

Investigation of the clinical breakpoints of piperacillin–tazobactam against infections caused by Pseudomonas aeruginosa by Yamagishi, Yuka, Terada, Michinori, Ohki, Emiko, Miura, Yoko, Umemura, Takumi, Mikamo, Hiroshige

“…Abstract The pharmacokinetics–pharmacodynamics (PK–PD) breakpoint of piperacillin/tazobactam (PIPC/TAZ) for hospital-acquired pneumonia (HAP) and Pseudomonas…”
Get full text

Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib by Gemma, Akihiko, Kusumoto, Masahiko, Kurihara, Yasuyuki, Masuda, Noriyuki, Banno, Shigeo, Endo, Yutaka, Houzawa, Hiroyuki, Ueno, Naomi, Ohki, Emiko, Yoshimura, Akinobu

“…The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally available…”
Get more information

Clinical application of azithromycin extended-release (ER) formulation to treat female sexually transmitted infection by Terada, Michinori, Ohki, Emiko, Yamagishi, Yuka, Mikamo, Hiroshige

“…The prevalence of female sexually transmitted infection (STI) in Japan is in the decreasing tendency after 2002, however it still actualizes as a social…”
Get more information

Antifungal susceptibility of Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole by Yamagishi, Yuka, Terada, Michinori, Ohki, Emiko, Mikamo, Hiroshige

“…We investigated antifungal susceptibility of 96 Candida species strains (37 strains of Candida albicans, 30 of Candida glabrata, 16 of Candida tropicalis and…”
Get more information

Developing Artificial Intelligence Models for Extracting Oncologic Outcomes from Japanese Electronic Health Records by Araki, Kenji, Matsumoto, Nobuhiro, Togo, Kanae, Yonemoto, Naohiro, Ohki, Emiko, Xu, Linghua, Hasegawa, Yoshiyuki, Satoh, Daisuke, Takemoto, Ryota, Miyazaki, Taiga

“…Introduction A framework that extracts oncological outcomes from large-scale databases using artificial intelligence (AI) is not well established. Thus, we…”
Get full text

Antimicrobial activity of oral quinolones against clinical isolates of Bifidobacterium group and Clostridium difficile by Kimura, Masao, Yamagishi, Yuka, Terada, Michinori, Ohki, Emiko, Tanaka, Kaori, Watanabe, Kunitomo, Mikamo, Hiroshige

“…Administrations of antimicrobial agent influence human intestinal flora, and sometimes lead to cause Clostridium difficile colitis (CDC). It has been well…”
Get more information

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study by Sato, Kazuo, Toyoshima, Yasuharu, Moriyama, Shiho, Endo, Yutaka, Ito, Tetsuhide, Ohki, Emiko

“…Background Sunitinib is approved for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) in patients with unresectable,…”
Get full text

Real-world treatment response in Japanese patients with cancer using unstructured data from electronic health records by Araki, Kenji, Matsumoto, Nobuhiro, Togo, Kanae, Yonemoto, Naohiro, Ohki, Emiko, Xu, Linghua, Hasegawa, Yoshiyuki, Inoue, Hirofumi, Yamashita, Sakiko, Miyazaki, Taiga

“…Purpose We generated methods for evaluating clinical outcomes including treatment response in oncology using the unstructured data from electronic health…”
Get full text

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer by Nishio, Makoto, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Solomon, Benjamin J, Shaw, Alice T, Hashigaki, Satoshi, Ohki, Emiko, Usari, Tiziana, Paolini, Jolanda, Polli, Anna, Wilner, Keith D, Mok, Tony

“…Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and…”
Get full text

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors by Takahashi, Toshiaki, Boku, Narikazu, Murakami, Haruyasu, Naito, Tateaki, Tsuya, Asuka, Nakamura, Yukiko, Ono, Akira, Machida, Nozomu, Yamazaki, Kentaro, Watanabe, Junichiro, Ruiz-Garcia, Ana, Imai, Keiji, Ohki, Emiko, Yamamoto, Nobuyuki

“…Summary Background Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4…”
Get full text

Final phase II results for sunitinib (SU) in Japanese pts with well-differentiated pancreatic neuroendocrine tumor (NET) by Ito, Tetsuhide, Okusaka, Takuji, Tori, Masayuki, Hashigaki, Satoshi, Kimura, Nobuyuki, Ohki, Emiko, Sawaki, Akira, Nishida, Toshirou, Yamao, Kenji, Imamura, Masayuki

Get full text